Geetha Subramaniam

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

Joshua D. Lee, Edward V. Nunes, Patricia Novo et al. · The Lancet · 2017 · 681 citations · Full text

Opioid Epidemic, Comparative Effectiveness, Substance Abuse +10

Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth

George Woody, Sabrina Poole, Geetha Subramaniam et al. · JAMA · 2008 · 351 citations · Full text

Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use Screening in Primary Care Patients

Jennifer McNeely, Li‐Tzy Wu, Geetha Subramaniam et al. · Annals of Internal Medicine · 2016 · 291 citations · Full text

Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients

William S. John, He Zhu, Paolo Mannelli et al. · Drug and Alcohol Dependence · 2018 · 126 citations

Family Medicine, Substance Abuse, Primary Care +13

Randomized Controlled Trial of Osmotic-Release Methylphenidate With Cognitive-Behavioral Therapy in Adolescents With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders

Paula Riggs, Theresa Winhusen, Robert D. M. Davies et al. · Journal of the American Academy of Child & Adolescent Psychiatry · 2011 · 125 citations

Osmotic-release Methylphenidate, Adhd, Psychopathology +14